Equity Details
Price & Market Data
Price: $54.03
Daily Change: +$0.04 / 0.07%
Daily Range: $52.46 - $54.51
Market Cap: $7,801,242,112
Daily Volume: 1,260,030
Performance Metrics
1 Week: -2.89%
1 Month: -12.50%
3 Months: -1.73%
6 Months: 29.72%
1 Year: 71.04%
YTD: 17.10%
About Vaxcyte, Inc. (PCVX)
A complete market overview for Vaxcyte, Inc. (PCVX). The stock is at 54.03, with a daily change of +$0.04 / 0.07%. Market cap: 7,801,242,112. Delve into its YTD and 3-month performance.
Company Details
Employees: 507
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.